CClinicalTrials.gg
RecruitingNCT07640243Updated Jun 10, 2026

Sedation Methods in Percutaneous Transhepatic Biliary Drainage: Procedure Quality and Recovery

An interventional study of Remifentanil and Ketamine in Fragility, Biliary Obstruction and Cholangitis, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This prospective, randomized, single-center study aims to evaluate and compare two different sedation and analgesia regimens used during percutaneous transhepatic biliary drainage (PTBD) procedures. A total of 96 adult patients undergoing elective PTBD or biliary stenting will be randomized to receive either propofol-remifentanil or propofol-ketamine sedation. The primary outcome is recovery time assessed using the Modified Aldrete Score. Secondary outcomes include procedure quality, pain scores, patient and operator satisfaction, hemodynamic stability, and the incidence of sedation-related adverse events. The study is designed to determine the optimal sedation strategy for PTBD, particularly in fragile and elderly patient populations.

Read the detailed description

Percutaneous transhepatic biliary drainage (PTBD) is a therapeutic procedure commonly performed in patients with biliary obstruction when surgical intervention or endoscopic retrograde cholangiopancreatography is not feasible. These patients frequently present with advanced age, malignancy, cholangitis, and significant comorbidities, making them particularly vulnerable to sedation-related complications.

Procedural sedation and analgesia are commonly used during interventional radiology procedures to ensure patient comfort, immobility, and procedural success. However, inadequate sedation may result in patient movement, increased anxiety, procedural failure, and complications, whereas excessive sedation may lead to hemodynamic instability, respiratory depression, and delayed recovery, especially in frail patients.

In this study, two commonly used sedation regimens-propofol combined with remifentanil and propofol combined with ketamine-will be compared. Both regimens are routinely used in non-operating room anesthesia settings in our institution. Patients will be randomly assigned in a 1:1 ratio to one of the two groups. Standard monitoring will be applied, including non-invasive blood pressure, electrocardiography, and pulse oximetry, with supplemental oxygen administered via nasal cannula.

Sedation depth will be targeted to a Ramsay Sedation Score of 3-4 and assessed every five minutes during the procedure. Hemodynamic parameters, oxygen saturation, pain scores, recovery time, and adverse events such as hypotension, bradycardia, hypoxia, nausea, vomiting, and airway interventions will be recorded. Recovery will be evaluated using the Modified Aldrete Score at two-minute intervals until adequate recovery is achieved.

The primary objective of the study is to compare recovery times between the two sedation regimens. Secondary objectives include comparison of pain intensity, patient and operator satisfaction, total drug consumption, procedural tolerance, and incidence of adverse events. The findings of this study aim to contribute to safer and more effective sedation strategies for PTBD procedures in high-risk patient populations.

02

Conditions studied

  • Fragility
  • Biliary Obstruction
  • Cholangitis
  • Malignancy

Keywords

  • FRAGILITY
  • Percutaneous Transhepatic Biliary Drainage
  • SEDATION
  • KETAMINE
  • REMİFENTANIL
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Scheduled for elective percutaneous transhepatic biliary drainage (PTBD) and/or biliary stenting
  • ASA physical status II-IV
  • Fasting time of at least 6 hours prior to the procedure
  • Ability to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Inability to provide informed consent or to complete study assessments (e.g., Ramsay Sedation Scale, FRAIL scale, Numeric Rating Scale)
  • Clinical diagnosis of Alzheimer's Disease
  • Clinical diagnosis of demantia
  • Known allergy or hypersensitivity to propofol, remifentanil, ketamine, ondansetron, or deksketoprofen
  • Grade 3-4 aortic, mitral, or tricuspid valve disease
  • Advanced or decompensated heart failure (ejection fraction \<25%)
  • Emergency procedures
  • Refusal to participate in the study
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Propofol-Remifentanil

    Participants received intravenous propofol 0.5 mg/kg followed by a continuous intravenous remifentanil infusion initiated at 0.10-0.18 mcg/kg/min during the procedure. The remifentanil infusion rate was adjusted within the specified range according to clinical response to maintain adequate sedation, analgesia, and hemodynamic stability throughout the procedure.

    Drug: Remifentanil

  • Experimental
    Propofol-Ketamine

    IParticipants received intravenous propofol 0.5 mg/kg followed by intravenous ketamine 0.3 mg/kg. Additional intravenous ketamine 5 mg was administered every 5 minutes as needed during the procedure to maintain the target sedation level and hemodynamic stability.

    Drug: Ketamine

Interventions

  • DrugRemifentanil

    Intravenous propofol combined with remifentanil infusion for procedural sedation during percutaneous transhepatic biliary drainage.

  • DrugKetamine

    Intravenous propofol combined with ketamine bolus for procedural sedation during percutaneous transhepatic biliary drainage.

05

What researchers measure

Primary outcomes

  1. Recovery Time

    Time to achieve adequate recovery assessed using the Modified Aldrete Score.

    Time frame: From completion of the procedure until Modified Aldrete Score >8, assessed up to 30 minutes

Secondary outcomes

  1. Hemodynamic Stability

    Changes in systolic, diastolic, and mean arterial blood pressure, heart rate, and oxygen saturation during the procedure.

    Time frame: Baseline, every 5 minutes during the procedure (assessed up to 60 minutes), and immediately after the procedure.

  2. Pain Intensity

    Pain intensity assessed using the Numeric Rating Scale (NRS)

    Time frame: Baseline (pre-procedure), immediately after recovery, and at 30 minutes post-recovery.

  3. Sedation Depth

    Sedation level assessed using the Ramsay Sedation Scale.

    Time frame: Every 5 minutes during the procedure, assessed up to 30 minutes.

  4. Adverse Events

    Incidence of sedation-related adverse events including hypotension, bradycardia, hypoxia, apnea, nausea, and vomiting.

    Time frame: Perioperatively and through the recovery period, assessed up to 30 minutes.

  5. Patient and Operator Satisfaction

    Patient and operator satisfaction assessed after completion of the procedure.

    Time frame: Immediately after the procedure

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07640243
Lead sponsor
Ankara City Hospital Bilkent
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Feb 1, 2026
Primary completion
May 30, 2026 (estimated)
Completion
Jun 10, 2026 (estimated)
Last update
Jun 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion